Elahere (mirvetuximab soravtansine)

​For the treatment of adult patients with folate receptor-alpha (FRα) positive*, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.